Cortexyme, Inc.
Cortexyme, Inc. is listed today as IRulya Therapeutics Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| May 2026 | $115 M | Private placement after listing | $50 to $250 million | equity, options | SEC | |
| Jun 2025 | $11 M | Private placement after listing | $10 to $50 million | equity, options | SEC | |
| May 2018 | $84 M | No. 2 | $50 to $250 million | equity | SEC | |
| Dec 2015 | $8 M | No. 1 | $2 to $10 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Cortexyme, Inc. chose not to state its revenue in its newest notice of a funding round (Jun 2026).
SEC Form D · Jun 2026
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Jun 2026
That is all the official record says: Cortexyme, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of Cortexyme, Inc. are on record.
Investors#
8 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| David Lamond | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2019) | SEC Form 3 |
| Pfizer Inc | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Pfizer Strategic Investment Holdings LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Pfizer Ventures (US) LLC | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Takeda Pharmaceutical Co LTD | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Takeda Pharmaceuticals International AG | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | Company | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
| Takeda Ventures, Inc. | Venture capital | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2019) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 36 investors.
Largest shareholders today
Institutions holding IRulya Therapeutics Inc. shares, as of Sep 30, 2026.
- Janus Henderson Group Ltd.$53 M15.82%
- Ikarian Capital, LLC$3 M0.88%
- Squadron Capital Management LLC$3 M0.83%
- Millennium Management LLC$2 M0.67%
- Balyasny Asset Management L.P.$2 M0.65%
- Acuta Capital Partners, LLC$2 M0.49%
- Birchview Capital, LP$1 M0.37%
- Boothbay Fund Management, LLC$1 M0.20%
- Jane Street Group, LLC$1 M0.19%
- Seven Fleet Capital Management LP$0 M0.11%
- Geode Capital Management, LLC$0 M0.09%
- Vanguard Capital Management LLC$0 M0.09%
- Cormorant Asset Management, LP$0 M0.05%
- Vanguard Fiduciary Trust Co$0 M0.05%
- BlackRock, Inc.$0 M0.02%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Brendan Hannah | Executive officer | Jun 2026 |
| Brigette Roberts | Executive officer | Jun 2026 |
| Charles Ryan | Executive officer | Jun 2026 |
| Dirk Thye | Executive officer | Jun 2026 |
| Casey Lynch | Executive officer | May 2018 |
| Kristen Gafric | Executive officer | May 2018 |
| Brigette Roberts | Director | Jun 2026 |
| Christopher Senner | Director | Jun 2026 |
| David Lamond | Director | Jun 2026 |
| Dirk Thye | Director | Jun 2026 |
| June Bray | Director | Jun 2026 |
| Luca Benatti | Director | Jul 2025 |
| Margi McLoughlin | Director | Jul 2025 |
| Rajiv Patni | Director | Jul 2025 |
| Una Ryan | Director | Jul 2025 |
| Casey Lynch | Director | May 2018 |
| Ilan Zipkin | Director | May 2018 |
| Roger Quy | Director | May 2018 |
| Stephen Dominy | Director | May 2018 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.